When to Order Imaging for Imaging of the Axilla: ACR Appropriateness Decoded
When to Order Imaging for Imaging of the Axilla: ACR Appropriateness Decoded
A patient presents with a new, palpable lump in their axilla. The differential is broad, ranging from benign reactive lymphadenopathy to metastatic disease. Deciding on the most appropriate initial imaging study is critical for timely diagnosis and management, but can be challenging given the multiple available modalities. Choosing incorrectly can lead to diagnostic delays, unnecessary radiation exposure, or costly workups. This guide distills the American College of Radiology (ACR) Appropriateness Criteria for imaging of the axilla, providing clear, evidence-based recommendations to help you select the right test for the right clinical scenario.
What Does ACR Imaging of the Axilla Cover?
This ACR guideline focuses on the evaluation of the axilla in several distinct clinical contexts, primarily in adult female patients. The recommendations cover the initial workup of palpable axillary lumps, both unilateral and bilateral, as well as the crucial role of axillary imaging in the staging and treatment response assessment of breast cancer. This includes scenarios for newly diagnosed breast cancer of varying sizes and nodal status, evaluation during and after neoadjuvant chemotherapy, and assessment of locally recurrent disease.
The criteria also address the next steps when a suspicious axillary node is incidentally identified on another imaging study. This guideline does not cover routine breast cancer screening or the evaluation of non-lump axillary symptoms like pain or skin changes without a palpable finding. It is specifically tailored to diagnostic dilemmas centered on axillary lymphadenopathy and its relationship to breast pathology.
What Imaging Should I Order for Imaging of the Axilla? Recommendations by Clinical Scenario
The optimal imaging strategy for the axilla depends entirely on the clinical presentation. The ACR provides specific guidance for common scenarios to guide decision-making.
For a female with a new palpable, unilateral, axillary lump, the ACR rates US axilla as Usually appropriate. Ultrasound is the ideal first step as it involves no radiation and can effectively characterize the lump, differentiate a lymph node from other soft tissue structures, and guide biopsy if needed. In this context, diagnostic mammography or digital breast tomosynthesis (DBT) May be appropriate to evaluate for an occult breast primary, but cross-sectional imaging like MRI or CT is Usually not appropriate for initial evaluation.
In the case of a new palpable, bilateral, axillary lump, US axilla remains Usually appropriate. Bilateral findings often suggest a systemic or reactive process rather than a primary breast malignancy, and ultrasound is excellent for confirming and characterizing the lymphadenopathy without radiation. Other imaging modalities are rated Usually not appropriate for this initial workup.
In patients with newly diagnosed breast cancer, axillary imaging is key for staging. For small tumors (2 cm or less) that are clinically node-negative, axillary US May be appropriate but is not always required. However, if the patient is clinically node-positive, US axilla becomes Usually appropriate to confirm suspicious nodes and facilitate biopsy. For larger tumors (greater than 2 cm), even if clinically node-negative, US axilla May be appropriate, as is MRI breast without and with IV contrast for comprehensive staging. If the patient with a large tumor is clinically node-positive, US axilla is Usually appropriate, while MRI, CT, and FDG-PET/CT all become options that May be appropriate for systemic staging.
For patients undergoing neoadjuvant chemotherapy, if a new palpable axillary lump develops mid-treatment, US axilla is Usually appropriate to assess for disease progression. After completion of neoadjuvant therapy, imaging helps plan surgery. For initially node-positive patients, US axilla is Usually appropriate to restage the axilla. For initially node-negative patients, both MRI breast without and with IV contrast and US axilla May be appropriate to evaluate treatment response.
Finally, if a suspicious axillary node is found on mammography or ultrasound, the next step is tissue sampling. Both US-guided core biopsy and US-guided fine needle aspiration (FNA) are rated Usually appropriate. If a suspicious node is seen on another modality like CT or MRI, the first step is correlation with targeted US axilla, which is Usually appropriate, along with diagnostic mammography or DBT.
ACR Imaging Recommendations Table
| Clinical Scenario | Top Procedure | ACR Rating | Adult RRL | Pediatric RRL |
|---|---|---|---|---|
| Female. New palpable, unilateral, axillary lump. Initial imaging of the axilla. | US axilla | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. New palpable, bilateral, axillary lump. Initial imaging of the axilla. | US axilla | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Newly diagnosed breast cancer, 2 cm or less, with clinical node-negative. Initial imaging of the axilla following diagnostic mammography or DBT. | US axilla | May be appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Newly diagnosed breast cancer, 2 cm or less, with clinical node-positive. Initial imaging of the axilla following diagnostic mammography or DBT. | US axilla | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Newly diagnosed breast cancer, greater than 2 cm, with clinical node-negative. Initial imaging of the axilla following diagnostic mammography or DBT. | US axilla | May be appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Newly diagnosed breast cancer, greater than 2 cm, with clinical node-positive. Initial imaging of the axilla following diagnostic mammography or DBT (prior to treatment). | US axilla | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Breast cancer, greater than 2 cm in size, at mid-treatment of neoadjuvant chemotherapy, with initial clinical node-negative disease but now presenting with new palpable axillary lump. Imaging of the axilla at mid-treatment. | US axilla | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Breast cancer, greater than 2 cm in size, clinical node-negative. Imaging of the axilla after completion of neoadjuvant chemotherapy. | MRI breast without and with IV contrast | May be appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Breast cancer, greater than 2 cm in size, clinical node-positive. Imaging of the axilla after completion of neoadjuvant chemotherapy and prior to surgery. | US axilla | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Newly diagnosed locally recurrent breast cancer. Initial imaging of the axilla following diagnostic mammography or DBT. | US axilla | May be appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Suspicious axillary node on mammography or ultrasound. Next imaging study. | US-guided core biopsy axillary node | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
| Female. Suspicious axillary node on any other imaging modality (excluding mammography and ultrasound). Next imaging study. | US axilla | Usually appropriate | O 0 mSv | O 0 mSv [ped] |
Adult vs. Pediatric Imaging of the Axilla Imaging: Radiation Dose Tradeoffs
The ACR guidelines for imaging of the axilla are primarily focused on adult female patients, as breast cancer and related axillary evaluation are rare in the pediatric population. However, the principles of radiation safety are universal. For nearly all scenarios presented, the recommended initial studies (ultrasound, MRI) are radiation-free, denoted by a Relative Radiation Level (RRL) of ‘O 0 mSv’. This makes them inherently safe for all age groups.
In the rare instances where ionizing radiation studies like CT or PET/CT are considered, adherence to the As Low As Reasonably Achievable (ALARA) principle is paramount, especially in younger patients. The ACR provides distinct pediatric RRLs for these studies. For example, a CT of the chest, abdomen, and pelvis has an adult RRL of ☢ ☢ ☢ ☢ (10-30 mSv), while the pediatric RRL is lower at ☢ ☢ ☢ ☢ (3-10 mSv). This reflects the use of dose-reduction techniques and weight-based protocols essential in pediatric imaging to minimize the lifetime risk of radiation-induced malignancy.
Imaging Protocol Details for Imaging of the Axilla
Once you’ve decided on the right study, the specific imaging protocol is essential for diagnostic accuracy. Our protocol guides provide detailed, practical information on technique, contrast administration, and interpretation principles for key studies recommended in this guideline.
Tools to Help You Order the Right Study
Navigating imaging guidelines can be complex. GigHz offers a suite of tools designed to support evidence-based clinical decision-making at the point of care.
For scenarios not covered here, the ACR Appropriateness Criteria Lookup provides a comprehensive, searchable interface for all ACR guidelines. To ensure the study you order is performed correctly, the Imaging Protocol Library offers detailed, institution-agnostic protocols for hundreds of imaging procedures. When discussing studies that involve ionizing radiation, the Radiation Dose Calculator is a valuable tool for estimating cumulative exposure and communicating radiation risk to patients.
Why is ultrasound the first-line study for a palpable axillary lump?
Ultrasound is the preferred initial imaging modality because it uses no ionizing radiation, is widely available, and provides excellent high-resolution detail of soft tissues. It can reliably distinguish lymph nodes from other structures like cysts or lipomas, assess nodal morphology (e.g., cortical thickness, loss of fatty hilum) to determine suspicion for malignancy, and provide real-time guidance for biopsy if necessary.
When is diagnostic mammography or DBT indicated for an axillary lump?
Diagnostic mammography or Digital Breast Tomosynthesis (DBT) is rated as ‘May be appropriate’ for a new unilateral axillary lump. Its primary role is to search for an occult (non-palpable) primary breast cancer that may be the source of axillary metastasis. This is especially important if the ultrasound shows a suspicious lymph node without any other clear cause.
What does the ‘(Disagreement)’ tag on an ACR rating signify?
The ‘(Disagreement)’ tag indicates that while the expert panel reached a consensus on the final appropriateness rating (e.g., ‘May be appropriate’), there was a notable minority opinion among the panel members. This highlights that the role of the procedure in that specific clinical scenario may be controversial or evolving, and that clinical judgment and multidisciplinary discussion are particularly important when considering that imaging option.
For a suspicious axillary node, is a core biopsy or fine needle aspiration (FNA) preferred?
The ACR rates both US-guided core biopsy and US-guided FNA as ‘Usually appropriate’ for sampling a suspicious axillary node. The choice often depends on institutional preference and the clinical question. FNA is faster and less invasive, providing cytologic samples. A core biopsy obtains a larger tissue sample, preserving tissue architecture, which is often preferred for a definitive histologic diagnosis and is necessary for ancillary studies like hormone receptor testing if breast cancer metastasis is confirmed.
Why are CT and PET/CT usually not appropriate for an initial, isolated axillary lump?
For the initial evaluation of an isolated axillary lump without a known cancer diagnosis, CT and PET/CT are ‘Usually not appropriate’. These studies involve significant radiation exposure and have lower specificity for this indication compared to ultrasound. Many benign conditions (e.g., reactive or infectious adenopathy) can cause FDG uptake on a PET scan, leading to false positives. These powerful systemic staging tools are reserved for patients with a confirmed malignancy to look for distant disease, not for the initial characterization of a localized finding.
Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026
